Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Hum Psychopharmacol
; 24(4): 301-8, 2009 Jun.
Article
en En
| MEDLINE
| ID: mdl-19387994
ABSTRACT
OBJECTIVE:
Risperidone is converted to 9-hydroxyrisperidone by CYP2D6. Two parameters were used to examine the influences of CYP2D6 polymorphism and of co-medication on risperidone metabolism the risperidone9-hydroxyrisperidone concentration ratio (R9-OHR ratio) and the sum of the risperidone and 9-hydroxyrisperidone concentrations divided by the dose (CD ratio). We evaluated the effect of the CYP2D6*10 allele, which is a prevalent mutant allele among East Asians.METHODS:
Genotyping using the P450 microarray system was performed for 89 Japanese patients with schizophrenia receiving risperidone. The patients with CYP2D6*1/*1, *1/*2, or *2/*2 were classified as Group 1, those with one CYP2D6*10 allele (CYP2D6*1/*10 or *2/*10) were classified as Group 2, and those with two CYP2D6*10 alleles were classified as Group 3. The R9-OHR and CD ratios were analyzed using two-way ANOVAs with the CYP2D6 genotype and co-medication with CYP2D6-dependent drugs as independent variables.RESULTS:
Both the "genotype" and the "co-medication" factors had significant impacts on the R9-OHR ratio (p = 0.011, p < 0.001). The "genotype" factor also had a significant impact on the CD ratio (p = 0.032). However, the "co-medication" factor did not have a significant impact on the CD ratio (p = 0.129).CONCLUSIONS:
The CYP2D6*10 polymorphism and the presence of co-medication exerted significant influences on the pharmacokinetics of risperidone.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esquizofrenia
/
Antipsicóticos
/
Risperidona
/
Citocromo P-450 CYP2D6
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Hum Psychopharmacol
Asunto de la revista:
PSICOFARMACOLOGIA
Año:
2009
Tipo del documento:
Article
País de afiliación:
Japón